C
1.07
0.11 (12.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Chemomab Therapeutics Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.00 |
|
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 15.27% |
| 机构持股比例 | 16.93% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Wetzel Investment Advisors, Inc. | 31 Dec 2024 | 10,000 |
| Moser Wealth Advisors, Llc | 31 Dec 2024 | 500 |
| 52周波幅 | ||
| 中 | 25.00 (2,243.68%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Oppenheimer | 27 Aug 2025 | 25.00 (2,243.68%) | 购买 | 3.48 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合